Development and validation of a multiplex molecular assay for rapid detection of opportunistic fungal pathogens in immunocompromised patients

Project Abstract

The rapid and accurate identification of opportunistic fungal pathogens in immunocompromised patients remains a critical clinical challenge, often hindered by low fungal burden, slow culture-based methods, and the emergence of antifungal resistance. This study reports the development and comprehensive validation of a multiplex molecular assay designed to detect and differentiate major opportunistic fungi, including Candida species, Aspergillus spp., Cryptococcus neoformans, Pneumocystis jirovecii, and Mucorales, directly from clinical specimens. The assay utilizes a panel of conserved fungal gene targets and species-specific singleplex primers combined in a closed-tube, real-time PCR format to enable simultaneous, high-throughput detection with rapid turnaround. Analytical performance was characterized using quantified reference materials and a diverse panel of clinical isolates, demonstrating limits of detection in the range of 1–10 CFU equivalents per reaction for Candida and Aspergillus targets and 10–100 copies for Pneumocystis jirovecii, with robust specificity against a broad spectrum of bacterial flora and commensal yeasts. A comprehensive in silico in silico validation complemented by wet-lab cross-reactivity testing confirmed minimal cross-reactivity and preserved performance in the presence of potential PCR inhibitors commonly found in respiratory, blood, and sterile body fluids. The study then evaluated clinical performance prospectively in 350 anonymized patient samples across three tertiary care centers, spanning bronchoalveolar lavage, sputum, blood, and cerebrospinal fluid specimens from immunocompromised individuals. The multiplex assay demonstrated a sensitivity of 94.6% and a specificity of 97.8% for all fungal targets when benchmarked against composite reference standards that integrated culture results, conventional 18S rRNA PCR, and expert mycological review. Subgroup analyses revealed near-perfect detection for Aspergillus fumigatus and Candida albicans, while detection for Pneumocystis jirovecii showed the highest concordance in respiratory specimens with characteristic low fungal load. The assay significantly reduced time-to-result, delivering qualitative outcomes within 2.5 hours from specimen receipt versus 48–72 hours with culture-based methods, thereby enabling earlier antifungal decision-making and optimization of antifungal stewardship. Reproducibility and inter-laboratory validation demonstrated consistent performance across operators and instruments, with a coefficient of variation below 5% for Ct values of all targets. The assay also supported semi-quantitative estimation of fungal burden through Ct value interpretation, facilitating risk stratification in severely immunocompromised patients. Limitations include occasional discordant results in mixed-species infections and reduced sensitivity for rare filamentous fungi not included in the panel, suggesting potential for periodic panel updates. Overall, the multiplex molecular assay provides a rapid, accurate, and scalable diagnostic tool for comprehensive fungal pathogen detection in immunocompromised hosts, with significant implications for timely antifungal therapy initiation, improved patient outcomes, and enhanced infection control.

Project Overview

What This Project Is About

---

A plain-language overview of the topic and what the project investigates.

---

---

The Problem It Addresses

---

What problem or gap this project tackles and why it matters to the field or society.

---

---

Objectives of the Project

---

1. Identify common opportunistic fungal pathogens that affect immunocompromised patients.
2. Develop a multiplex molecular assay that detects multiple pathogens in a single test.
3. Validate the assay’s accuracy, speed, and reliability against standard methods.
4. Assess the assay’s practicality for clinical lab use and potential cost benefits.
5. Provide guidelines for interpretation of results in patient care settings.

---

---

What You Will Do Step by Step

---

1. Review existing diagnostic methods for fungal infections and note limitations.
2. Select target fungal species based on prevalence and clinical relevance.
3. Design primers and probes for a multiplex assay capable of detecting chosen pathogens.
4. Develop and optimize the assay in the lab using control samples.
5. Test sensitivity, specificity, and cross-reactivity with a range of clinical specimens.
6. Compare results with conventional methods to evaluate accuracy.
7. Analyze data to determine assay performance metrics (e.g., limit of detection).
8. Evaluate workflow practicality, including time, equipment needs, and costs.

---

---

Expected Outcome

What result or solution is expected at the end of the project and what impact it will have.